Calculation of Long-Term Cardiovascular Health Benefit and Cost Saving from Systolic Blood Pressure Reduction in Hypertension Patients

doi:10.19546/j.issn.1674-3830.2025.7.014

China Health Insurance ›› 2025, Vol. 0 ›› Issue (7) : 105-110. DOI: 10.19546/j.issn.1674-3830.2025.7.014

Author information +

History +

Abstract

Objective: The paper calculates and analyzes the numerical relationship between systolic blood pressure (SBP) reduction in hypertension patients after treatment intervention with long-term cardiovascular health benefit and medical cost saving, providing an effective decision-making basis for the value evaluation, reasonable pricing, and clinical application of new pharmaceutical technologies. Methods: Based on disease progression of hypertension, a Markov model was established to analyze the improvement of long-term cardiovascular risks due to SBP reduction, and consequently to calculate the incremental quality-adjusted life years (QALYs) and medical cost saving. Sensitivity analysis was conducted. Results: After treatment intervention, for male hypertension patients, 1mmHg reduction in SBP could bring 0.0047 incremental QALYs and 319.34 yuan of cost saving; for hypertension patients, 1mmHg reduction in SBP could bring 0.0035 incremental QALYs and 219.97 yuan of cost saving. Sensitivity analysis suggested the results were robust. Conclusion: SBP reduction in hypertension patients could bring clear long-term health benefits and cost-saving. The numerical results could be used to support healthcare decision-making.

Key words

chronic disease management / health benefits / medical costs

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

Calculation of Long-Term Cardiovascular Health Benefit and Cost Saving from Systolic Blood Pressure Reduction in Hypertension Patients[J]. China Health Insurance. 2025, 0(7): 105-110 https://doi.org/10.19546/j.issn.1674-3830.2025.7.014

References

[1] NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants[J]. Lancet, 2021,398(10304):957-980.
[2] 赵冬. 中国成人高血压流行病学现状[J].中国心血管杂志,2020,25(06):513-515.
[3] 刘明波,何新叶,杨晓红,等.《中国心血管健康与疾病报告2023》要点解读[J].临床心血管病杂志,2024,40(08):599-616.
[4] CHOBANIAN A V, BAKRIS G L, BLACK H R, et al.Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure[J]. Hypertension, 2003, 42(6): 1206-1252.
[5] ETTEHAD D,EMDIN C A. KIRAN A, et al.Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis[J]. Lancet, 2016, 387(10022):957-967.
[6] VERDECCHIA P, GENTILE G, ANGELI F, et al.Influence of blood pressure reduction on composite cardiovascular endpoints in clinical trials[J]. Journal of hypertension, 2010, 28(7):1356-1365.
[7] EKMAN M, BIENFAIT-BEUZON C, JACKSON J.Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden[J]. Journal of human hypertension, 2008, 22:845-855.
[8] D'AGOSTINO R B, VASAN R S, PENCINA M J, et al. General cardiovascular risk profile for use in primary care: the Framingham heart study[J]. Circulation, 2008, 117(6): 743-753.
[9] 胡宏飞,周挺,李冯,等.健康价值评估中质量调整生命年的替代及优化方法介绍与比较[J].中国新药杂志,2024,33(19):1969-1975.
[10] GROSSO A M, BODALIA P N, MACALLISTER RJ, et al.Comparative clinical-and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review, meta-and cost-utility analysis[J]. International journal of clinical practice, 2011, 65(3):253-263.
[11] 刘国恩. 中国药物经济学评价指南[M].北京:中国市场出版社,2020:16-17.
[12] 田葳. 高血压患者门诊费用及影响因素分析[D].沈阳:沈阳医学院,2022.
[13] 陈静晗. 基于Markov模型对高血压治疗药物的药物经济学评价[D].桂林:桂林电子科技大学,2022.
[14] 段承阿鑫,隋宾艳,艾丹丹,等.阿利沙坦酯治疗原发性高血压的临床综合评价[J].中国合理用药探索,2022,19(03):46-55.
[15] 刘叶倩,赵艳蛟,陈永法.2021—2023年我国药物经济学评价研究述评[J].卫生经济研究,2024,41(08):20-22+26.
[16] 陶立波. 质量与信任:在我国开展与应用医药经济学评价的策略探讨[J].中国医疗保险,2017(06):53-56.
[17] D'AGOSTINO R B, WOLF P A, BELANGER A J, et al. Stroke risk profile: adjustment for antihypertensive medication[J]. Stroke, 1994, 25(1):40-43.
[18] 吴红红,段磊,山努佳,等.老年高血压患者脉压差对肾脏损害的影响研究[J].中国全科医学,2011,14(18):2022-2024.